- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05885607
Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure (EMAS-HF)
The goal of this observational study is to learn about SGLT2 inhibition medications in patients with symptomatic heart failure who are clinically prescribed FDA-approved SGLT2 inhibitors. The main question it aims to answer is:
- What are the impacts of SGLT2 inhibition on systemic metabolomic and proteomic profiles? Participants will be asked to do the following before and after being prescribed a SGLT2i.
- Six-minute walk testd
- Calf MRI with plantar flexion exercise
- Blood sample collection
Study Overview
Status
Detailed Description
Schema
Total anticipated enrollment: 40 participants This is an observational study in patients being initiated on an FDA-approved SGLT2i treatment for symptomatic HF (on-label use). This observational study involves supplemental research testing before and after SGLT2i initiation to help define how the treatment affects the body.
Study Design
This will be a single-center study that will characterize early changes in systemic metabolic and proteomic profiles, skeletal muscle oxidative capacity and six-minute walk distance before and after initiation of SGLT2i treatment. The paired study design will specifically target patients with symptomatic heart failure whose physicians are prescribing FDA-approved SGLT2i treatment. Pre- vs. post-treatment profiling will be performed during the first 4-8 weeks of therapy. Eligibility is not limited to a particular range of LVEF or affected by prior LVEF.
Visit Procedures
Visit 1: Enrollment/Baseline Visit
- Eligibility/Informed Consent
- Medical History, Medications Review
Visit 2: Pre-SGLT2i Testing
- Blood sample collection
- Six-minute walk test
- Calf MRI with plantar flexion exercise
Visit 3: Post-SGLT2i Testing
- Blood sample collection
- Six-minute walk test
- Calf MRI with plantar flexion exercise
Study Objectives
Primary
- Assess the impact of SGLT2i on systemic metabolomic and proteomic profiles
Secondary
- Assess the impact of SGLT21 on ambulation
- Assess the impact of SGLT2i on skeletal muscle oxidative phosphorylation capacity (SkM OxPhos)
- Assess the impact of SGLT2i on skeletal muscle perfusion during exercise
Study Endpoints
- We will measure changes in venous concentrations of metabolic substrates and intermediates, along with circulating proteomic regulators using both targeted and untargeted surveys.
- Differences in distance traveled during a standardized 6 minute walk test.
- OxPhos as assessed using CrCEST MRI spectroscopy
- MRI-based assessment of SkM Perfusion: Differences in conduit artery blood flow and intramuscular perfusion using vPIVOT MRI imaging
Risks and Benefits Overview
As an observational study, the risks of this research are confined to those associated with the supplemental testing that is being performed: blood sampling, six-minute walk testing and MRI scanning with foot flexion exercise. Blood sampling and six-minute walk testing have minimal risk. After eliminating individuals with absolute contraindications to MRI scanning, such as retained metal fragments or implanted devices that are not MRI compatible, risks related to this MRI study are limited and include feeling uncomfortable in the MRI scanner and developing minor leg discomfort from the one-foot exercise required. Individuals with implanted pacemakers or defibrillators designated as "MRI-conditional" may be included. Subjects who are not eligible for MRI studies may still participate in the blood sampling and six-minute walk test assessments
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jacob Wilsey
- Phone Number: 2156624214
- Email: jacob.wilsey@pennmedicine.upenn.edu
Study Contact Backup
- Name: Emily Marvel
- Phone Number: 2156153236
- Email: emily.marvel@pennmedicine.upenn.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥18 years
- Clinically diagnosed HF documented in the patient's medical record
- NYHA Class II-III functional status, according to the most recent clinical evaluation
- Availability of an echocardiogram or cardiac MRI within the prior year
- Stable HF medical therapy (no change in beta-blocker, ACE/ARB, ARNI or MRA for at least 4 weeks prior to screening) with the exception of diuretics
- Planned initiation of on-label SGLT2i therapy
Exclusion Criteria:
- Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrollment or previous intolerance to an SGLT2 inhibitor
- Subject inability/unwillingness to perform a six-minute walk test
- Acute coronary syndrome or unstable angina within the past month
- Previous cardiac transplantation or implantation of a ventricular assist device
- Any condition that will interfere with the completion of the study. This may include comorbid conditions or logistical factors that may impede successful completion of the protocol (e.g. inability to travel for follow-up visits)
Absolute Exclusions for the Leg MRI Assessment (may still participate in blood sampling and six-minute walk testing):
- ANY intracranial implants of any type other than dental fillings
- ANY non-removable piercings, jewelry, or medicinal patch
- ANY personal history of intraocular injury or fragment in or around the orbit that cannot be cleared through radiologic examination
- ANY personal history of bullet, shrapnel, or stabbing wounds that cannot be cleared through radiologic evaluation.
- ANY non-removable life assist device, pump, or prosthetic
Possible Exclusions** for the Leg MRI Assessment (may still participate in blood sampling and six-minute walk testing):
- An intra-luminal implant, filter, stent, or valve replacement
- A vascular clip or clamp
- A surgically placed clip, clamp or band on visceral organs
- A cardiac pacemaker or implanted cardiac defibrillator (ICD)##
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the impact of SGLT2i on systemic metabolomic and proteomic profiles
Time Frame: 4-8 weeks
|
We will measure changes in venous concentrations of metabolic substrates and intermediates, along with circulating proteomic regulators using both targeted and untargeted surveys.
SGLT2i has been shown to impact glucose, fatty acid, and ketone metabolism.
|
4-8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the impact of SGLT21 on ambulation
Time Frame: 4-8 weeks
|
Differences in distance traveled during a standardized 6-minute walk test.
Changes in systemic or skeletal muscle metabolism may improve walking distance.
|
4-8 weeks
|
Assess the impact of SGLT2i on skeletal muscle oxidative phosphorylation capacity (SkM OxPhos)
Time Frame: 4-8 weeks
|
OxPhos as assessed using CrCEST MRI spectroscopy.
SkM OxPhos is a major topic of interest for this proposal.
We hypothesize that SGLT2i may improve skeletal muscle OxPhos.
|
4-8 weeks
|
Assess the impact of SGLT2i on skeletal muscle perfusion during exercise
Time Frame: 4-8 weeks
|
MRI-based assessment of SkM Perfusion: Differences in conduit artery blood flow and intramuscular perfusion using vPIVOT MRI imaging.
Changes in dynamic responses of SkM blood flow may be a contributor to the improvements in exercise tolerance we hypothesize will occur with SGLT2i
|
4-8 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kenneth Margulies, MD, University of Pennsylvania
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 853146
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
US Department of Veterans AffairsCompleted
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey